PDT Partners LLC Buys 97,539 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

PDT Partners LLC raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 385.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 122,842 shares of the company’s stock after acquiring an additional 97,539 shares during the quarter. PDT Partners LLC’s holdings in Cellebrite DI were worth $2,706,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. NewEdge Advisors LLC raised its holdings in Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after acquiring an additional 3,352 shares during the period. R Squared Ltd bought a new stake in shares of Cellebrite DI during the 4th quarter valued at $100,000. Polen Capital Management LLC purchased a new stake in Cellebrite DI during the 4th quarter worth about $222,000. Victory Capital Management Inc. bought a new position in Cellebrite DI in the 4th quarter worth about $234,000. Finally, HighTower Advisors LLC purchased a new position in Cellebrite DI during the 4th quarter valued at about $274,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CLBT. Lake Street Capital raised their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. increased their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $23.43.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $20.10 on Wednesday. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30. The stock has a market cap of $4.81 billion, a P/E ratio of -14.46, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The firm’s fifty day moving average price is $18.76 and its 200-day moving average price is $20.15.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.